Prevalence and clinical relevance of sarcopenia in Chinese patients with porto-sinusoidal vascular disorder

中国门静脉窦血管疾病患者肌少症的患病率及临床意义

阅读:1

Abstract

AIM: Porto-sinusoidal vascular disorder (PSVD) is a rare vascular liver disease that has similar manifestations to liver cirrhosis. However, limited information is available on the prevalence and clinical impacts of sarcopenia in patients with PSVD in China. METHODS: We enrolled 92 patients with PSVD from West China Hospital between January 2019 to June 2024 to analyze and characterize the burden of sarcopenia. The psoas muscle mass index (PMI), measured at the third lumbar vertebra (L3-PMI, cm(2)/m(2)), was used for quantitative analysis of skeletal muscle mass. Age- and sex- specific cut-off values, optimized for the Chinese population, were endorsed for the diagnosis of sarcopenia. RESULTS: Sarcopenia was observed in 17 out of the 92 PSVD patients (18.5%). The sarcopenia group had a higher proportion of patients with a history of esophagogastric variceal bleeding (EGVB) compared to the non-sarcopenia group (88.24% vs. 60.0%, p = 0.046). Transjugular intrahepatic portosystemic shunt (TIPS) creation significantly increased L3-PMI [4.84 (3.70-5.44) vs. 5.10 (4.40-6.10), p = 0.0153]. During the 1-year follow-up after endoscopic treatment, the cumulative incidence of rebleeding was significantly higher in the sarcopenia group than in the non-sarcopenia group [HR 4.39, 95% CI 1.01-19.10, log-rank p = 0.0485]. Multivariate Cox regression analysis showed that sarcopenia was an independent predictor of 1-year variceal rebleeding. CONCLUSION: Sarcopenia is common in patients with PSVD, particularly among those with a history of EGVB. TIPS placement may potentially enhance the muscle mass of PSVD patients. Importantly, sarcopenia appears to negatively impact clinical outcomes in PSVD patients undergoing endoscopic therapy for variceal bleeding.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。